Implantable Cardioverter Defibrillators Market: as Medtronic's Aurora EV-ICD compounds real-world evidence toward broader adoption and Boston Scientific's EMPOWER leadless pacemaker continues accumulating one-year trial data still short of its originally targeted 2025 FDA approval, the extravascular and modular therapy categories are advancing at genuinely different speeds, so buyers tracking only headline approval dates risk missing which platform is actually closer to changing standard of care.

The global implantable cardioverter defibrillators market size was USD 7.84 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period.Medtronic reported that its Cardiac Rhythm and Heart Failure division net sales increased 7 percent in fiscal year 2025, with growth driven by Micra transcatheter pacing systems, the Aurora extravascular implantable cardioverter defibrillator system, and TYRX, partially offset by declines in CRT-D products.The Medtronic Aurora EV-ICD MRI SureScan received US FDA Pre-Market Approval on October 20, 2023, with Medtronic management projecting the EV-ICD market to reach USD 1 Billion within 10 years of launch.The World Health Organization documented that cardiovascular diseases account for an estimated 17.9 million deaths annually, with sudden cardiac deaths representing 40 to 50% of all cardiovascular deaths, establishing the fundamental clinical demand base for ICD therapy.Boston Scientific's EMBLEM S-ICD system has achieved more than 130,000 worldwide implants, establishing a significant commercially implanted global base of subcutaneous ICD patients who represent future candidates for the mCRM upgrade pathway.Medtronic's Q3 FY2025 earnings release reported over 70% growth in the Aurora EV-ICD within the Cardiac Rhythm and Heart Failure segment, confirming rapid commercial acceleration of extravascular ICD adoption.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single ICD platform widens its addressable revenue every time it accumulates real-world evidence supporting broader physician confidence, converting cautious early adoption into mainstream referral pathway acceptance without a new device approval.Once a novel ICD system class like the extravascular Aurora has cleared its pivotal FDA approval, each subsequent real-world registry publication that confirms the pivotal trial's safety and efficacy findings reduces the remaining adoption hesitancy among electrophysiologists who were waiting for evidence beyond the controlled trial population, so revenue compounds as real-world confidence accumulates on top of the original regulatory approval.As a result, demand and revenue share are concentrating around platforms that pair regulatory approval with the fastest-accumulating real-world evidence base, and the forecast distinguishes between platforms still awaiting their first FDA approval and those already compounding post-approval confidence.For instance, at Heart Rhythm 2026, Medtronic presented one-year results from the Enlighten real-world study of the Aurora EV-ICD system, showing high anti-tachycardia pacing success, effective defibrillation, and an improved inappropriate shock rate in real-world practice, building directly on the pivotal trial data that supported the original 2023 FDA approval.These are some of the key factors driving revenue growth of the market.

Because Medtronic's large-scale EHR analysis of more than one million patients showed that devices were implanted in only 16.7% of indicated men and 12.7% of indicated women in the United States, this reflects systemic gaps in cardiology referral pathways that leave the majority of clinically eligible patients without guideline-recommended ICD therapy.

High per-unit device cost is a second constraint, with ICD systems costing USD 15,000 to USD 50,000 per implantation procedure, combined with surgical complication risks including pneumothorax, cardiac perforation, and lead-related infection, creating barriers to adoption in lower-income markets and among frail elderly patients.

Extended generator battery longevity is a third constraint, as longer-lasting ICD generators reduce the replacement procedure volume that historically generated recurring revenue from generator replacement surgeries at end of device service life.

These factors substantially limit implantable cardioverter defibrillators market growth over the forecast period.

The clearest driver of demand is the accumulation of real-world evidence confirming the Aurora EV-ICD's pivotal trial performance outside the controlled study population. A novel ICD system class only converts from early-adopter interest to mainstream referral pathway acceptance once electrophysiologists see real-world data matching pivotal trial results, and Medtronic's Enlighten post-approval registry, presented at Heart Rhythm 2026, showed exactly that: high ATP success, effective defibrillation, and an improved inappropriate shock rate in everyday clinical practice. Medtronic's OmniaSecure defibrillation lead, described as the world's smallest defibrillation lead at 4.7 Fr, received FDA approval for right ventricle placement in April 2025 and launched commercially in early 2026, then received expanded FDA approval for left bundle branch area conduction system pacing shortly before Heart Rhythm 2026. The Aurora EV-ICD's original FDA approval was supported by the global pivotal Extravascular ICD study published in the New England Journal of Medicine, demonstrating 98.7% effectiveness with no major complications compared to traditional ICDs. The effect on the market is that Medtronic now offers both extravascular and enhanced transvenous defibrillation solutions from the same commercial relationship, allowing physicians to match device selection to individual patient anatomy and risk profile. These are some of the key factors driving revenue growth of the market.

The second driver, and an important nuance for buyers to track, is that Boston Scientific's modular leadless pacing concept is still awaiting its first FDA approval even as its clinical evidence base continues to mature. A modular CRM system only earns FDA approval once its full trial dataset, not just interim results, demonstrates consistent safety across the complete follow-up period, and Boston Scientific's MODULAR ATP trial one-year outcomes, published in Circulation: Arrhythmia and Electrophysiology in November 2025, extended the evidence base beyond the original ESC 2024 six-month data that had supported the company's 2025 approval target. Boston Scientific's EMBLEM S-ICD system has achieved more than 130,000 worldwide implants, creating a structural competitive advantage for the eventual mCRM upgrade pathway because existing EMBLEM patients could receive a future EMPOWER Leadless Pacemaker implant without a completely new ICD system implantation. Separately, Abbott's AVEIR CSP LP, a leadless conduction system pacemaker currently in early human feasibility studies, received FDA Breakthrough Device designation in 2025, signalling a third major vendor's entry into next-generation leadless cardiac rhythm management technology. The effect on the market is that the modular and leadless conduction pacing categories are advancing on genuinely different regulatory timelines across three major vendors, and buyers should track approval status directly rather than assuming originally targeted dates were met. These are some of the key factors driving revenue growth of the market.

“Boston Scientific's MODULAR ATP trial one-year outcomes were published in November 2025, extending the evidence base beyond the original ESC 2024 six-month data, but as of the most recent product disclosures the EMPOWER Leadless Pacemaker remained an investigational device still pursuing its originally targeted 2025 FDA approval.”

However, the implantable cardioverter defibrillators market faces severe adoption constraints from chronic underutilisation of ICD therapy, high per-unit device cost, and extended generator battery longevity.

Because devices were implanted in only 16.7% of indicated men and 12.7% of indicated women in Medtronic's large-scale EHR analysis, this reflects systemic gaps in cardiology referral pathways, patient acceptance, and geographic access to electrophysiology services.

High per-unit device cost is a second constraint, with ICD systems costing USD 15,000 to USD 50,000 per implantation procedure creating barriers to adoption in lower-income markets and among frail elderly patients where the procedural risk-benefit calculus is less favourable.

Extended generator battery longevity is a third constraint, as modern transvenous ICDs offering 7 to 10 year battery service life, and the Aurora EV-ICD's comparable longevity design, reduce replacement procedure volume relative to prior technology generations.

These factors substantially limit implantable cardioverter defibrillators market growth over the forecast period.

Based on product type, the global ICD market is segmented into transvenous ICDs, subcutaneous ICDs, extravascular ICDs, and wearable cardioverter defibrillators. Transvenous ICDs account for approximately 72% of 2025 market revenue. The CRT-D sub-segment experienced revenue decline in FY2025, driven by longer-lasting CRT-D generators that reduce replacement procedure frequency. Extravascular ICDs represent the fastest-growing ICD product category, driven by Aurora EV-ICD commercial adoption and the platform's over 70% revenue growth in Q3 FY2025.

The S-ICD category, led by Boston Scientific's EMBLEM platform with 130,000+ worldwide implants, is expected to undergo a significant commercial inflection when the mCRM upgrade pathway receives FDA approval, as the large existing EMBLEM installed base would generate upgrade procedure revenue without requiring de-novo ICD system implantation. Until that approval occurs, EMBLEM S-ICD revenue growth depends on new implant volume alone rather than the additional upgrade pathway revenue the mCRM system is designed to unlock.

Based on regional analysis, the ICD market in North America accounted for the largest revenue share in 2025 at approximately 44% of global revenue. The United States drives the regional position through the highest per-unit ICD system pricing globally, the largest electrophysiology procedure volume in the world, and CMS reimbursement of ICD implantation procedures under MS-DRG 226 and MS-DRG 227 at rates of USD 20,000 to USD 45,000 per admission. Medtronic's published analysis showing that only 50.5% of ICD-indicated patients were referred to an electrophysiologist, and 44.3% of referred patients received a device, establishes a structural market expansion opportunity if referral pathway improvements increase device adoption rates.

The market in Europe is expected to register a rapid revenue growth rate in the global ICD market over the forecast period.

Germany, France, the United Kingdom, Italy, and the Netherlands represent the five largest national ICD markets within Europe. The European Society of Cardiology guidelines recommend ICD implantation in Class I for patients with left ventricular ejection fraction of 35% or below and symptomatic heart failure despite optimal medical therapy, establishing the guideline-driven clinical indication that drives ICD procurement. Medtronic's European commercial infrastructure distributes the CE Mark-approved Aurora EV-ICD system to European EP centres, while Boston Scientific's EMPOWER LP component remains pending CE Mark alongside its US regulatory pathway.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global ICD market over the forecast period.

Japan, China, South Korea, and Australia represent significant national ICD markets within the region, with rising cardiovascular disease burden and expanding electrophysiology infrastructure investment driving procedure volume growth. China's expanding tertiary hospital cardiac electrophysiology programme development and growing reimbursement coverage for ICD implantation are extending device access beyond the region's most developed urban centres.

Latin America and Middle East and Africa markets are expected to register moderate revenue growth rates in the global ICD market over the forecast period.

Brazil and Mexico represent the two largest national ICD markets in Latin America, with cardiovascular disease burden driving demand concentrated at private and academic tertiary hospital electrophysiology programmes. Saudi Arabia and the UAE represent the primary GCC markets, with the Saudi Vision 2030 healthcare investment programme supporting new hospital construction and associated electrophysiology programme development.